Global Age-related Macular Degeneration (AMD) Drugs Market Size, Trend & Opportunity Analysis Report, by Product (Eylea, Lucentis), Disease (Wet AMD, Dry AMD), Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy), and Forecast, 2025-2035
Global Age-related Macular Degeneration (AMD) Drugs Market Size, Opportunity Analysis and Forecast, 2025 - 2035
Introduction and Definition
Global Age-related Macular Degeneration (AMD) drugs market is expected to showcase a huge leap from a valuation of USD 11.71 billion in 2024 to USD 28.73 billion by 2035, at a CAGR of 8.50% throughout the forecast period (2025-2035). AMD is one of the foremost avoidable causes of blindness in the elderly, resulting in clinical urgency and innovation in drug development. Growing instances of AMD due to an aging population and lifestyle-induced risk factors such as smoking and hypertension have created a strong emphasis on early intervention and new drug delivery systems worldwide.
This market growth is enhanced by the awareness campaigns, advanced diagnostic techniques such as optical coherence tomography (OCT), and improved access to anti-VEGF therapy. The prescription of drugs such as Eylea (aflibercept) and Lucentis (ranibizumab), which drastically improve overall outcomes by significantly retarding disease progression particularly in cases of Wet AMD, heralds a new treatment paradigm. The burden imposed by high treatment costs, the requirement of repetitive intravitreal injections, and inconsistent patient adherence to therapy have provoked pharmaceutical innovators to search for durable formulation and extended-release options.
Yet in the same light, newer therapies begin to shine some focus on the somewhat neglected Dry AMD segment. Companies are investing heavily in drugs in late-stage pipeline development that target complement inhibition and oxidative stress modulation. The gradual shift toward precision ophthalmology with AI-assisted diagnosis and pharmacogenomic personalization will only serve to magnify the role of AMD therapeutics in improving patients' quality of life and delaying vision decline among aging citizens around the globe.
Recent Developments in the Industry
- In April 2024, Roche announced the European Medicines Agency-s approval of Vabysmo- (faricimab) for the treatment of Wet AMD, citing its dual inhibition mechanism and bi-monthly dosing as game-changing attributes in real-world patient adherence.
- In October 2023, Iveric Bio received FDA approval for Zimura- (avacincaptad pegol), an intravitreal complement C5 inhibitor indicated for geographic atrophy, a late-stage form of Dry AMD. This represents one of the first targeted therapies for a largely underserved AMD subtype.
- In July 2023, Bayer and Regeneron unveiled promising results from their Phase III trial of high-dose aflibercept 8 mg for Wet AMD, demonstrating comparable efficacy with fewer injections, potentially revolutionizing the treatment burden landscape.
- In March 2023, Apellis Pharmaceuticals initiated global Phase IV surveillance for Syfovre-, targeting Dry AMD patients with geographic atrophy, reflecting increasing industry attention to unmet needs beyond Wet AMD.
Market Dynamics
Increasing Geriatric Population and Lifestyle Diseases Boost the Demand for AMD Therapeutics
The rise above 65 years old is now global and is projected to increase to over 1.5 billion by 2050, with a direct impact on the incidence of AMD about its risk factors. Age is a new factor in the general list of risk factors, such as smoking, obesity, cardiovascular diseases, and diabetes, setting up earlier onset and faster progression rates, pushing the demand for a wider armamentarium of treatment. Loss of vision in the elderly is becoming more burdensome, both socio-economically and governmentally-setting health providers are adopting AMD drugs within public reimbursement schemes more aggressively.
Breakthrough Therapies and Long-Acting Drugs Transforming the Landscape of AMD Treatment
The market experiences such a significant transformation with the introduction of long-acting anti-VEGF therapies and dual-pathway drugs. Spells targeting vascular endothelial growth factor-A (VEGF-A), angiopoietin-2, and complement pathways call out more durably meaningful visual gains with less frequent treatment application. Long-standing compliance issues are addressed by this evolving trend while unlocking enormous potential for wider patient segments-residing in rural or underserved healthcare geographies.
Expanded Access via Teleophthalmology and Specialty Pharmacy Speeds Up Market Entry
Modern digital platforms and teleophthalmology enable a major bulk of the AMD screening and follow-up process. Remote diagnostics and AI-supported fundus imaging may allow ophthalmologists to far more efficiently triage and treat their patients suspected of suffering from AMD. Meanwhile, the growth of specialty pharmacy models and home-delivery services is helping patients keep to their drug regimens and simplifying the logistics of repeat doses, thereby reinforcing revenue continuity for market players.
R&D Investments and Regulatory Incentives Energize Pipeline Growth for Dry AMD Drugs
Considering the lack of treatment options for both Dry AMD and geographic atrophy, the companies dedicated to pharmaceutical research and development of novel interventions are upbeat. Public funding agencies and fast-track regulatory designations help accelerate timelines to market entry. Investing more funds in biotech companies that are predominantly into gene therapy, stem-cell modulation, and neuroprotection is very interesting it greatly diversifies the market opportunity.
Attractive Opportunities in the Market
- Dry AMD Drug Innovation - Rising prevalence demands urgent solutions for geographic atrophy management.
- Long-Acting Injectables - Reduced dosing frequency offers improved compliance and cost-effectiveness.
- AI Diagnostics - Imaging-based algorithms enhance early AMD detection and clinical decision-making.
- Digital Distribution Channels - Online pharmacies improve access, especially in remote elderly populations.
- Combination Therapies - Multi-targeted mechanisms enhance efficacy in late-stage AMD.
- Biologic and Biosimilar Launches - Cost reduction strategies open up emerging markets.
- Global Screening Initiatives - Government-led eye health programs increase drug uptake.
- Patient Education Campaigns - Vision awareness efforts drive early diagnosis and sustained treatment.
- Emerging Markets Growth - Expanding elderly base fuels AMD demand in Asia-Pacific and Latin America.
- Regenerative Therapy Prospects - Stem cell and gene therapies promise long-term vision restoration.
Report Segmentation
- By Product: Eylea, Lucentis
- By Disease: Wet AMD, Dry AMD
- By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
- By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
- Key Market Players: Roche, Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Iveric Bio, Apellis Pharmaceuticals Inc., Adverum Biotechnologies Inc., Bausch + Lomb, Ocuphire Pharma Inc., Kubota Vision Inc.
Report Aspects
- Base Year: 2024
- Historic Years: 2022, 2023, 2024
- Forecast Period: 2025-2035
- Report Pages: 293
Dominating Segments
Eylea Leads the AMD Drugs Market with Broad Indication and Established Safety Profile
Due to its flexible dosing options, broad availability, and established efficacy, Eylea is leading the competition in AMD drugs. Its status as a first-line treatment in parts of the world has been confirmed by its established use in the treatment of Wet AMD. Other factors for its success include its reimbursement base and high degree of clinician faith from its robust real-world and clinical trial validation data.
Lucentis maintains a position with a tremendous global reach and penetration in specialty markets.
Another cornerstone therapy, Lucentis, has continued to hold strong across developed economies because it possesses high therapeutic reliability and specificity for anti-VEGF-A action. The same did Lucentis, continuing to deliver to patients through government health schemes, hospital procurement programs, and specialty pharmacies. Moreover, that inclusion by combining therapy and those modified formulations for considering the condition diabetic macular edema is another relevance to sustaining use.
Wet AMD Segment Drives Market Revenue with High Treatment Adoption and Clear Clinical Pathways
Wet AMD remains the primary revenue generator within the AMD drugs market, bolstered by clearly defined diagnostic criteria, high risk of vision loss, and availability of targeted therapeutics. The initiation and frequency of injections for Wet AMD have high urgency, thus translating into greater expenditure from a per-patient perspective. Innovations focusing on fewer injections without compromising efficacy have sealed the growth potential for this segment.
However, the dry AMD segment is now beginning to hold out as an engine of future growth with the advances of the pipeline. Generally neglected in the past, the Dry AMD market is starting to show commercial traction on account of the first regulatory approvals of drugs directed at geographic atrophy. The knowledge of disease mechanisms in combination with increased awareness of patients has encouraged big pharma and biotech to speed up drug development in this area. Promising molecules are making their way toward launch, thus setting this segment ready for high-profile growth over the next decade.
Distribution Channels Extending through Online Pharmacies and Hospital-Tethered Specialty Outlets
Hospital pharmacies remain the major distribution mechanism for AMD medications, especially for cases of Wet AMD that require ongoing clinical supervision. Yet specialty pharmacies and online platforms are aggressively acquiring market share by providing greater patient support services, auto-refill features, and remote delivery, most importantly to elderly patients with mobility constraints. These changes are bringing about the transformation of how AMD therapeutics are assessed around the world and adhered to.
Key Takeaways
- Wet AMD Dominance - Strong treatment adoption drives revenue from anti-VEGF therapies.
- Dry AMD Pipeline Growth - Rising approvals address long-underserved patient segment.
- Hospital and Specialty Pharmacies Lead - Core distribution channels offer secure, monitored delivery.
- AI-Powered Eye Health - Diagnostic support tools enhance early detection and treatment planning.
- Digital Retail Surge - Online pharmacies facilitate medication access for aging populations.
- Longer-Acting Therapies - Bi-monthly or quarterly injectables improve treatment adherence.
- Government Screening Push - Public health efforts promote proactive AMD management.
- North America Retains Leadership - Advanced healthcare infrastructure supports drug adoption.
- Asia-Pacific Opportunity - Elderly population surge fuels market entry and expansion.
- Biotech Partnerships Rise - Innovation alliances unlock new therapeutic frontiers.
Regional Insights
North America Still Holds the Reigns with Early Diagnosis and Advanced Accessibility to Health Care
The AMD drugs market is led by North America, which combines well-funded healthcare systems and strong reimbursement frameworks, along with a broad network of ophthalmologists. In particular, the U.S. has adopted early AMD diagnosis programs and revealed a high adherence in both Wet and Dry AMD. Coupled with the continuous FDA product approvals and clinical trial actions, North America holds the reins in therapeutic innovations.
Europe Shows Market Steady Influx Due to the Supportive Policy of an Aging Population.
The progressive population age, coupled with national health insurance coverage and basic diagnostic infrastructure, has marked many European countries favourably in the take-up of AMD therapies. Countries such as Germany, France, and the UK are championing public awareness campaigns, facilitation of access to anti-VEGF injections, and integrated ophthalmic care, thereby turning themselves into bulwarks for both AMD drug sales and clinical trials.
Asia-Pacific Expected to Register the Fastest Market Growth with the Aging Boom and Infrastructure Investments
Asia-Pacific is on course for the most rapid growth in the AMD drugs market, owing to rapid aging across Japan, China, South Korea, and India. Rising disposable incomes, expanding health insurance coverage, and government initiatives in eye care screening further propel increasing treatment demand. Such investments include joint and regional pharmaceutical alliances focused on local ophthalmology practices.
Emerging Potential in LATAM and MEA amidst Increasing Public Health Awareness
The concept of integrating AMD into Latin America and the Middle East, and North Africa is taking shape slowly but surely into their health networks. However, there is still not much access at the moment to high-cost biologics. Yet, international aid programs, public-private partnerships, and generic entry have started boosting penetration. Gradual improvement in vision health campaigns, localized, is increasing the diagnosis and treatment rates in urban centers.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Wet AMD is currently the primary revenue generator due to established diagnostic criteria, high treatment urgency, and the widespread use of anti-VEGF therapies. However, the Dry AMD segment is emerging as a major growth engine following recent regulatory approvals for drugs targeting geographic atrophy (GA).
Eylea (aflibercept) and Lucentis (ranibizumab) are the market leaders. Eylea holds a dominant position due to its flexible dosing options and high clinician trust, while Lucentis maintains a strong global presence through government health schemes and specialty pharmacy networks.
To combat the burden of frequent intravitreal injections and inconsistent patient adherence, pharmaceutical innovators are developing long-acting injectables and dual-pathway drugs. For example, Roche’s Vabysmo offers bi-monthly dosing, and high-dose aflibercept 8 mg aims to provide efficacy with fewer injections.
In October 2023, the FDA approved Iveric Bio’s Zimura (avacincaptad pegol) for geographic atrophy, a late-stage form of Dry AMD. Additionally, Apellis Pharmaceuticals has initiated global surveillance for Syfovre, marking a shift toward addressing previously underserved Dry AMD subtypes.
The population over 65 is projected to exceed 1.5 billion by 2050. Since age is a primary risk factor for AMD, this demographic shift, combined with rising rates of lifestyle diseases like hypertension and diabetes, is creating sustained demand for advanced therapeutics.
AI-supported imaging and teleophthalmology are streamlining early detection and patient triaging. Furthermore, the rise of online pharmacies and specialty pharmacy models is improving medication adherence by offering auto-refill features and home delivery for elderly patients with mobility constraints.
While North America currently leads the market due to its advanced healthcare infrastructure, the Asia-Pacific region is projected to register the fastest growth. This is driven by a massive elderly population surge in countries like China, Japan, and India, alongside expanding health insurance coverage.
Key obstacles include the high cost of biologic therapies, reimbursement limitations, and the clinical complexity of developing drugs for Dry AMD. Additionally, patient compliance remains a challenge due to the invasive nature of repetitive intravitreal injections.
The market is shifting toward "precision ophthalmology," with heavy R&D investment in gene therapy, stem-cell modulation, and neuroprotection. These regenerative therapies promise long-term vision restoration and could potentially move the industry beyond maintenance treatments to curative solutions.
